Our client Carol Levenson quoted in Marketwatch: "Teva has grown through medium-sized acquisitions and expanded from generics to branded drugs. But its branded drug portfolio is highly concentrated in [the multiple-sclerosis drug] Copaxone, soon to face generic competition..."